AUTHOR=Kassabian Benedetta , Facco Monica , Miscioscia Alessandro , Carraro Samuela , Rinaldi Francesca , Gallo Paolo , Puthenparampil Marco 

TITLE=Case report: Breaking CNS immuno-privilege: TNFα-inhibitor triggers aseptic meningitis in a patient with rheumatoid arthritis

JOURNAL=Frontiers in Immunology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1432360

DOI=10.3389/fimmu.2024.1432360

ISSN=1664-3224

ABSTRACT=Disclosures: Benedetta Kassabian has nothing to disclose. A. Miscioscia received travel grant from Novartis, Sanofi-Genzyme, and Biogen. Samuela Carraro and Monica Facco have nothing to disclose. Puthenparampil Marco received travel grant from Novartis, Genzyme, Biogen, Teva, Almirall and Sanofi-Genzyme; he has been consultant for Sanofi-Genzyme, Novartis., Biogen. Rinaldi Francesca serves as an advisory board member of Biogen-Idec and has received funding for travel and speaker honoraria from Merck Serono, Biogen Idec, Sanofi-Aventis, Teva and Bayer Schering Pharma. Paolo Gallo reports grants and personal fees from Novartis, grants and personal fees from Almirall, grants and personal fees from Biogen Idec, grants and personal fees from Sanofi Genzyme, grants and personal fees from Teva, grants and personal fees from Merck Serono, grants from University of Padova, grants from Italian Ministry of Public Health, grants from Veneto Region of Italy, grants from Italian Association for Multiple Sclerosis, outside the submitted work.